Non-Alcoholic Steatohepatitis (NASH) Epidemiology Analysis and Forecast to 2032
Summary
Non-alcoholic steatohepatitis (NASH) is a subtype of non-alcoholic fatty liver disease (NAFLD) that is characterized by liver cell damage and inflammation (Sheka et al., 2020). NASH is often asymptomatic and is detected incidentally. A liver biopsy is required for diagnosis. NASH can occur with or without liver fibrosis and can progress to more serious liver disease. A total of 20% of NASH patients will develop cirrhosis and all NASH patients are at increased risk for hepatocellular carcinoma (Sheka et al., 2020).
Scope
- Non-alcoholic steatohepatitis report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for NASH in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of NASH. The diagnosed prevalent cases of NASH are segmented by age and sex. Additionally, the forecast is further segmented based on fibrosis stage and cirrhosis type. This report also provides the historical and 10-year forecasted total and diagnosed prevalent cases of NAFLD.
The NASH Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global NASH markets.
- Quantify patient populations in the global NASH markets to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for NASH therapeutics in each of the markets covered.
- Understand magnitude of the NASH population by age, sex, fibrosis stage, and cirrhosis type.
- About GlobalData
- 1 Non-Alcoholic Steatohepatitis: Executive Summary
- 1.1 Catalyst
- 1.2 Related reports
- 1.3 Upcoming reports
- 2 Epidemiology
- 2.1 Disease background
- 2.2 Risk factors and comorbidities
- 2.3 Global and historical trends
- 2.4 7MM forecast methodology
- 2.4.1 Forecast assumptions and methods
- 2.4.2 Forecast assumptions and methods: diagnosed prevalent cases of NAFLD
- 2.4.3 Forecast assumptions and methods: total prevalent cases of NAFLD
- 2.4.4 Forecast assumptions and methods: diagnosed prevalent cases of NASH
- 2.4.5 Forecast assumptions and methods: diagnosed prevalent cases of NASH by fibrosis stage.
- 2.4.6 Forecast assumptions and methods: diagnosed prevalent cases of NASH with compensated and decompensated cirrhosis.
- 2.5 Epidemiological forecast for non-alcoholic steatohepatitis (2022-32)
- 2.5.1 Diagnosed prevalent cases of NASH.
- 2.5.2 Age-specific diagnosed prevalent cases of NASH
- 2.5.3 Sex-specific diagnosed prevalent cases of NASH
- 2.5.4 Diagnosed prevalent cases of NASH by fibrosis stage.
- 2.5.5 Diagnosed prevalent cases of cirrhosis attributable to NASH.
- 2.6 Discussion
- 2.6.1 Epidemiological forecast insight
- 2.6.2 Obesity omission
- 2.6.3 COVID-19 impact.
- 2.6.4 Limitations of the analysis
- 2.6.5 Strengths of the analysis
- 3 Appendix
- 3.1 Bibliography
- 3.2 Primary research - high-prescriber survey
- 3.3 About the Authors
- 3.3.1 Epidemiologist
- 3.3.2 Reviewers
- 3.3.3 Vice President of Disease Intelligence and Epidemiology
- Contact Us
- List of Tables
- Table 1: Summary of newly added data types
- Table 2: Summary of updated data types
- Table 3: Non-alcoholic fatty liver disease activity score
- Table 4: Risk factors and comorbidities for CKD
- Table 5: High-prescribing physicians (non-KOLs) sur
- List of Figures
- Figure 1: 7MM, diagnosed prevalent cases of NASH, both sexes, N, all ages, 2022 and 2032
- Figure 2: 7MM, diagnosed prevalence of NASH, both sexes, %, all ages, 2012-32
- Figure 3: 7MM, sources used to forecast the diagnosed prevalent cases of
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook